ES2396764A1 - FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. - Google Patents

FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. Download PDF

Info

Publication number
ES2396764A1
ES2396764A1 ES201131754A ES201131754A ES2396764A1 ES 2396764 A1 ES2396764 A1 ES 2396764A1 ES 201131754 A ES201131754 A ES 201131754A ES 201131754 A ES201131754 A ES 201131754A ES 2396764 A1 ES2396764 A1 ES 2396764A1
Authority
ES
Spain
Prior art keywords
inhibiting
drugs
mapk
activation
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201131754A
Other languages
English (en)
Other versions
ES2396764B1 (es
Inventor
Federico MAYOR MENÉNDEZ
Cristina Murga Montesinos
Pedro Manuel CAMPOS MUELAS
Jacoba Johanna HEIJNEN
Anna Maria Agnes Antonius KAVELAARS
Antonio Morreale de León
Rubén GIL REDONDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201131754A priority Critical patent/ES2396764B1/es
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Priority to US14/355,545 priority patent/US9096554B2/en
Priority to JP2014539368A priority patent/JP2014532688A/ja
Priority to AU2012331016A priority patent/AU2012331016A1/en
Priority to KR1020147014457A priority patent/KR20140085580A/ko
Priority to BR112014010560A priority patent/BR112014010560A2/pt
Priority to CA2854349A priority patent/CA2854349A1/en
Priority to EP12846045.8A priority patent/EP2774613A4/en
Priority to PCT/ES2012/070762 priority patent/WO2013064714A1/es
Publication of ES2396764A1 publication Critical patent/ES2396764A1/es
Application granted granted Critical
Publication of ES2396764B1 publication Critical patent/ES2396764B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Fármacos inhibidores de p38 y aplicaciones. Se describen compuestos con estructura de benzooxadiazolil amina con capacidad para inhibir la activación o la actividad biológica de la proteín kinasa activada por mitógeno (MAPK) p38 y su empleo en el tratamiento de una enfermedad que puede ser aliviada mediante la inhibición de la activación o actividad biológica de dicha MAPK p38, por ejemplo, una enfermedad inflamatoria o una enfermedad que cursa con dolor.
ES201131754A 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. Active ES2396764B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES201131754A ES2396764B1 (es) 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
JP2014539368A JP2014532688A (ja) 2011-11-02 2012-10-31 ｐ３８を阻害するための薬物およびそれらの用途
AU2012331016A AU2012331016A1 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
KR1020147014457A KR20140085580A (ko) 2011-11-02 2012-10-31 p38을 억제하기 위한 약물 및 이의 적용
US14/355,545 US9096554B2 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
BR112014010560A BR112014010560A2 (pt) 2011-11-02 2012-10-31 drogas para inibir p38 e usos das mesmas
CA2854349A CA2854349A1 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
EP12846045.8A EP2774613A4 (en) 2011-11-02 2012-10-31 P38-INHIBITING PHARMACEUTICAL COMPOUNDS AND THEIR APPLICATIONS
PCT/ES2012/070762 WO2013064714A1 (es) 2011-11-02 2012-10-31 Fármacos inhibidores de p38 y aplicaciones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201131754A ES2396764B1 (es) 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.

Publications (2)

Publication Number Publication Date
ES2396764A1 true ES2396764A1 (es) 2013-06-19
ES2396764B1 ES2396764B1 (es) 2013-12-19

Family

ID=48191418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201131754A Active ES2396764B1 (es) 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.

Country Status (9)

Country Link
US (1) US9096554B2 (es)
EP (1) EP2774613A4 (es)
JP (1) JP2014532688A (es)
KR (1) KR20140085580A (es)
AU (1) AU2012331016A1 (es)
BR (1) BR112014010560A2 (es)
CA (1) CA2854349A1 (es)
ES (1) ES2396764B1 (es)
WO (1) WO2013064714A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
CN105979950A (zh) * 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282818A1 (en) * 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2010128156A1 (en) * 2009-05-08 2010-11-11 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
US20080039461A1 (en) 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
EP1545535A4 (en) 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
US20060019971A1 (en) 2003-09-30 2006-01-26 Higgins Linda S Treatment of cardiovascular disease with inhibitors of p38 kinase
JP2008545696A (ja) 2005-05-23 2008-12-18 スミスクライン・ビーチャム・コーポレイション 肥満の処置のためのｐ３８ｍａｒｋの阻害
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
GB0713311D0 (en) 2007-07-10 2007-08-22 Nene Group Plc Pallet racking shield
DE102007060008A1 (de) 2007-12-13 2009-06-18 Technolas Gmbh Ophthalmologische Systeme Bestimmung und Überwachumg von Laserenergie
WO2010083404A2 (en) 2009-01-16 2010-07-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Linked myc-max small molecule inhibitors
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282818A1 (en) * 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2010128156A1 (en) * 2009-05-08 2010-11-11 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication

Also Published As

Publication number Publication date
CA2854349A1 (en) 2013-05-10
ES2396764B1 (es) 2013-12-19
EP2774613A4 (en) 2015-04-22
US20140296308A1 (en) 2014-10-02
AU2012331016A1 (en) 2014-06-26
US9096554B2 (en) 2015-08-04
WO2013064714A8 (es) 2014-06-12
EP2774613A1 (en) 2014-09-10
WO2013064714A1 (es) 2013-05-10
BR112014010560A2 (pt) 2017-04-25
KR20140085580A (ko) 2014-07-07
JP2014532688A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
SA518391170B1 (ar) مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MX2019003619A (es) Formulaciones de bromocriptina.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2018007361A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
ES2396764A1 (es) FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
GEP20156332B (en) Pyrazoles as crth2 antagonists
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
PH12014502075A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
EP3053601A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER CONTAINING THE CYB5R3 GENE OR PROTEIN AS AN ACTIVE SUBSTANCE
EA201491991A1 (ru) Новая система высвобождения гидрофобных белков
WO2016096640A3 (en) Anti-cxcl12 antibody molecules and their uses

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2396764

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20131219